Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai Looks to Log Over 800 Billion Yen in FY2020, Lenvima as Key Growth Engine
Eisai aims to ring up revenues of more than 800 billion yen in FY2020 ending in March 2021 focusing on two therapeutic areas - dementia related diseases and neurodegenerative diseases, and oncology - CEO Haruo Naito said on March 3.…
To read the full story
Related Article
BUSINESS
- Japan Pharma Workforce Up Slightly; Generic Firms Drive Gains over 5 Years
April 10, 2026
- Zenyaku, Chugai to End Rituxan Co-Promotion in September
April 10, 2026
- Effexor’s GAD Nod Seen Boosting Diagnosis, Treatment in Japan: Expert
April 10, 2026
- MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
- Pfizer Japan Files Tukysa Label Expansion in Breast, Biliary Tract Cancers
April 9, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…